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Poster Session I S213Current management strategies are suboptimal and associated with
significant adverse effects. Patients undergoing alloSCT are pro-
foundly immunocompromised and do not respond to vaccination
with CMV antigens. Immunotherapy (IT) with CMV specific do-
nor-derived cytotoxic T lymphocytes (CTL) is effective after al-
loSCT, but is expensive, labor intensive, and difficult to replicate.
Non-toxic strategies are needed to improve outcomes. In earlier
studies, we showed that ex vivo expanded activated T cells (ATC)
armed with anti-CD3 anti-Her2/neu bispecific antibody (Her2Bi)
exhibit high levels of specific cytotoxicity directed at breast cancer
cell lines. Using this strategy, we tested ATC armed with anti-
CD3 (OKT3)  anti-CMV (Cytogam) bispecific antibodies
(CMVBi) to target and lyse CMV-infected fibroblasts. Normal do-
nor ATC were generated and armed with CMVBi. Specific cytotox-
icity was tested by 51Cr release using CMV-infected or uninfected
human fibroblasts. CMVBi alone, CMVBi-armed ATC (aATC),
and ATC alone were tested for their ability to kill. ATC were armed
with 0.001 to 500 ng of CMVBi/106ATC at effector:target (E:T)
from 3.125:1 to 25:1. IFNgEliSpot was used to assess IFNg secreting
cells in ATC and aATC after exposure to CMV-infected and unin-
fected fibroblasts. ATC armed with CMVBi as little as 0.001 ng/
106 ATC was significantly more cytotoxic than unarmed ATC.
There was higher cytotoxicity mediated by aATC as the multiplicity
of infection (MOI) increased in target cells. At all E:T, CMVBi arm-
ing at a dose of 50 ng/106 ATC exhibited dramatically higher lysis of
CMV-infected targets (MOI 1) than that exhibited by ATC alone.
Cytotoxicity mediated by unarmed and armed ATCwas background
in uninfected targets. Immunofluorescent studies showed that aATC
aggregated around GFP fluorescence-marked CMV-infected fibro-
blasts. Cytokine secretion analyzed by IFNg EliSpot confirmed im-
mune responses. The lack of MHC restriction in the mediation of
cytotoxicity, polyclonal targeting of multiple CMV antigens and
the simplicity of expanding donor T cells makes it easy to adapt
this effective strategy against CMV infection post alloSCT.162
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Adoptive transfer of virus-specific T cells can effectively restore
antiviral immunity after stem cell transplantation. However, proto-
cols for eliciting virus-specific T cells from existing memory T cells
of CMV-seropositive adult (CMVpos) donors have been ineffective
when applied to na€ıve cord blood (CB) transplant (CBT) recipients
due to absence of antigen-specific memory cells in these grafts.
We previously demonstrated that CMVpp65-specific T cells could
be generated from CB using a modified protocol and that 15/15
CB T cell lines recognized atypical epitopes of pp65. To test if na€ıve
T cells from CMV-seronegative donors (CMVnegs) also recognize
atypical epitopes, we again optimized our previous method.
CD45RA1 na€ıve T cells were selected from peripheral blood and
stimulated with pp65-pepmix-pulsed DC with IL7, IL12, and
IL15. For subsequent stimulations T cells were stimulated with
pp65-pepmix-pulsed EBV-LCL and IL15 or IL2. CMVpp65-spe-
cific T cells (CMV-CTL) expanded from 8 of 11 CMVnegs and
were primarily CD81 T cells (mean 71%). These T cells secreted
markedly more IFN-g in response to pp65 peptides (mean 224;
range: 38-611 SFC/1x105 cells) than to irrelevant peptides (mean
12;Range 3-37) as measured in Elispot assays. These T cells lysed
pp65-pulsed target cells (mean:48;Range:15-70%) but not negative
controls (mean 22;Range 4-40%) in cytotoxicity assays. As with
CB, CMVneg CMV-CTL were derived from na€ıve T cells and rec-
ognized only atypical pp65 epitopes. These findings raised the con-
cern that the viral epitopes presented by endothelial cells infectedwith CMV in patients might not present the atypical peptides recog-
nized by our CMV-CTL. We hypothesized that the epitopes pre-
sented to T cells by endothelial cells or other APCs after CMV
infection are different to those presented in our in vitro system.
We tested if different epitopes would dominate the na€ıve T cell re-
sponse to CMV AD169-infected fibroblasts and CMV VR1814-in-
fected DC. The responding na€ıve T cells were again specific for
atypical epitopes showing that these epitopes were indeed presented
by cells naturally infected with CMV. This reassured us that despite
their unusual repertoire, T cells derived from CB or CMVnegs
should control CMV infections.We are now evaluating their clinical
efficacy in recipients of CBT and soon Hematopoietic Stem Cell
Transplantation. These studies should determine if na€ıve T cells
primed in vitro are able to persist and establish memory in vivo.163
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First generation chimeric antigen receptors (CAR) usually combine
the antigenbindingdomainof amonoclonal antibodywith the z signal-
ing domain of theT cell receptor/CD3 complex.When expressed inT
cells, thoseCARprovide potent antigen-specific, nonMHC-restricted
effector function against tumor cells in vitro, but clinical trials have
shown limited expansion and persistence of these lymphocytes in
vivo. This limitation is likely attributable to the failure of these CAR
to fully activate T cells following target antigen engagement on tumor
cells, since tumors lack expression of costimulatorymolecules required
for sustainedT cell activation. Incorporation of costimulatory endodo-
mainswithin theCAR, such asCD28, increases proliferation and activ-
ity of themodifiedT cells in vitro andmay enhance their benefit in vivo
but, as yet, the relevanceand valueof thesemodifications inhumansub-
jects remains speculative.
We now present results from a phase I trial of T cells redirected to
CD19 given to patients with refractory/relapsed B-cell malignancies.
Patients were simultaneously infused with 2 autologous T cell prod-
ucts expressing CAR with identical CD19-specific exodomains. In
one product, the endodomain contained only the z sequence
(CAR.19z) while, in the second product, we added a costimulatory
CD28 domain (CAR.19-28z). We could thus directly measure and
compare the expansion, persistence and effectiveness of each cell
population in every patient. Six subjects have been treated at 3 cell
dose levels (Table). Persistence of CAR1 T cells was assessed in
blood by Q-PCR assays specific for each population.
Table 1. Characteristics of the infused CD19-redirected
CAR-bearing T cell products (N56)
Memory SpecificCD4+ CD8+Na€ıve
(CD45RA+)(CD45RO+
CD62L+)lysis
(20:1 E:T ratio)CAR.19z T cells 44 ± 23 49 ± 22 6 ± 5 50 ± 24 53 ± 10CAR.18-28z T cells 47 ± 26 48 ± 22 6 ± 6 47 ± 66 65 ± 19All numbers are shown as mean percentage6 standard deviation. T cell
products were generated by activation of autologous peripheral blood
mononuclear cells with immobilized OKT3, gene modification with ret-
roviral vectors encoding either CAR.19z or CAR.19-28z and ex vivo ex-
pansion for a median of 14 days (range 6-18) in the presence of IL-2.
Three dose levels have been administered: 2107, 1108 and 2108
cells of each product/m2.
All infusions were well tolerated. CAR.19-28z cells were detected at
a low level after infusion, but progressively increased 7- to 63-fold,
peaking at 1-2 wk, before declining to background levels over the
S214 Poster Session Iensuing 3 mo. By contrast, CAR.19z cells were barely detectable af-
ter infusion, showed no expansion and disappeared rapidly. Follow-
ing treatment, 2 patients had stable disease for up to 6 mo and 4 had
progressive disease.
In conclusion, infusion of both CAR.19z and CD19-28zT cells is
safe at the doses used. Direct comparison of each cell product in
individual patients showed that the CD28 endodomain enhances
expansion and persistence of the CAR T cells. The limited clinical
benefits suggest that additional modifications will be required and
our approach will allow these changes to be systematically evaluated
even in small-scale clinical studies.164
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There is increasing evidence for the role of BK virus in the aetiol-
ogy of haemorrhagic cystitis and renal impairment post haemo-
poietic stem cell transplant (HSCT). Cellular therapy for immune
reconstitution post HSCT has been used clinically for CMV, EBV
and adenovirus. Broadening the scope of viral targets in this type
of therapy is desirable to reduce the burden of opportunistic infec-
tions in this patient group.
Methods: Monocyte derived dendritic cells or peripheral blood
mononuclear cells were pulsed with mixes of overlapping peptides
covering the 5 BKV proteins (VP1, VP2, VP3, LTA and STA).
These were used to stimulate T cells on days 1 and 7 and cells
were cultured for 21 days with increasing doses of IL-2 from day
7. The cellular product was then analysed for phenotype, BKV spec-
ificity and functionality by examining cytokine production and
cytotoxicity.
Results: Cellular proliferation was seen in all donors, mean fold in-
crease in total viable cells was 5.9 fold. All cell products were mainly
CD3 cells (mean 94.1%) with individual variation in CD4:CD8 ratio
(ranges: CD4 9.7 to 97.5%; CD8 0.9 to 77%). T cell subsets analysis
showed the majority of cells to be Tem (mean 71.2%), with a sizable
minority of Tcm (mean 21.5%). Data on antigen specificity was
available in 11 of 15 cultures. Within cultures, BKV responsive cells
varied (CD3 mean 12.7%, CD8 mean 15.2%, CD4 mean 12.5%,).
There was heterogeneity in the specificity of cells to different BKV
proteins. Most responses were directed to VP1, LTA and STA
with smaller magnitude responses seen to VP2 and VP3. The quality
of the cytokine response was assessed bymultiparameter flow cytom-
etry for IFN-g, TNF and IL-2. In all cases, the percentage of cells
producing multiple cytokines to stimulation with BKV proteins
was high (for CD3 mean triple cytokine 37.5%, double 34.3% and
single 28.2%). Cytotoxicity was assessed using CD107a/b expression
and the CARE-LASS cell lysis assay. CD107 expression was present
in both CD8 and CD4. This was higher in CD8 cells and lysis of
antigen coated target cells correlatedwith the presence of CD107 ex-
pression on CD8 cells.
Discussion:The clinical utility of this product will be determined in
clinical trials of adoptive immunotherapy following HSCT or renal
transplantation. This method for large-scale expansion of BKV spe-
cific CTL could also be utilised for analysis of BKV targeted immune
responses and epitope identification.165
EXPANDED HUMAN INKT CELLS EXHIBIT TH2 POLARIZATION AND
DIRECT CYTOTOXICITY AGAINST HEMATOLYMPHOID TUMOR TARGETS
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Memphis, TNCD1d-restricted invariant NKT (iNKT) cells are rare but potent
innate regulatory cells capable of immune modulation after trans-
plantation via robust production ofTh1/Th2 cytokines, as well as tu-
mor immunosurveillance via direct cytotoxicity. Protocols to expand
iNKT cells and tailor their cytokine secretion would broaden
their application in transplant immunotherapy. We have optimized
a protocol for ex vivo expansion of highly purified human
CD31Va241 iNKT cells from a variety of cell sources including hu-
man peripheral blood (PB), bone marrow, and umbilical cord blood.
PB CD31Va241 iNKT cells (. 98% pure by sort) were expanded
using PB-derived autologous APCs, Va24-specific TCR stimulation
without added glycolipids, and low-dose IL-2 and IL-7. This results
inmean. 103-fold expansion, with peak yields at day 14-21 (range, 3
 106 - 7  107 iNKT cells from 103 - 104 starting CD31Va241
cells). Expanded iNKT cells are CD31CD4negVa241 and retain
viability in culture through day 49. At 21 days, these iNKT cells se-
crete high IL-10 and IL-5, moderate IL-4 and IFN-g, and low IL-2
and IL-13 in anti-CD2/CD3/CD28 bead-stimulated Luminex
supernatant assay. Day 21 expanded iNKT cells maintained an IL-
4hiIFN-glo phenotype even with potent Th1-polarizing stimuli
[100 ng/mL of the glycolipid ligand alpha-galactosyl ceramide (a-
GalCer)], and are dose-dependent suppressors of sorted autologous
CD31CD4negVa24neg (. 95% CD31CD81) responders in 72-hr
CFSE MLR. Non-glycolipid activation of day 21 iNKT cells in-
duced high levels of cytolytic effectormolecules, including granzyme
B. We measured cytotoxicity of activated day 21 iNKT cells follow-
ing co-incubation of iNKT cells versus control effector populations
with firefly luciferase-transduced RS4,11 andNalm6 (B-ALL),U937
(monocytic) and K562 (CML) targets. iNKT cell effectors (E) dem-
onstrated dose-dependent cytotoxicity against B-ALL targets (T)
(e.g. Nalm6: 31.2 69.1% at E:T 0.1:1, 32.6 64.4% at E:T 0.5:1,
48.565.7% at E:T 1:1), with no significant cytotoxicity against my-
eloid targets (e.g. K562: 12.3 61.6% at E:T 0.1:1, 14.9 63.0% at
E:T 0.5:1, 14.2 62.6% at E:T 1:1). Our results indicate that human
iNKT cells expressing high levels of Th2 and regulatory cytokines
can be potently expanded ex vivo without exogenous glycolipid stim-
ulation and exert significant cytotoxicity against B-ALL targets. This
supports their potential for application in anti-tumor or regulatory
immunotherapy in the pre- and post-transplant setting.166
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Adoptive cell transfer (ACT) of autologous tumor-infiltrating
lymphocytes (TIL) mediates tumor regression in 50% of Stage
IV melanoma patients previously refractory to all other types of
therapy. Further improvement of this therapy based on current
technology (using OKT3 and allogeneic PBMC) to propagate T
cells has reached a point of diminishing returns due to the techni-
cally cumbersome and resource-intensive production of TIL for
clinical administration. The extended culture times needed to gen-
erate sufficient numbers of TIL typically results in acquisition of
terminally-differentiated T cells with loss of effector memory
(EM) function and reduced antigen specificity, resulting in poor
in vivo persistence and reduced therapeutic potential. Compound-
ing this problem is that TIL cannot be expanded from many mel-
anoma patients, leaving them without an option for cellular
therapy. To improve ACT, here we show that K562 cells can func-
tion as artificial antigen-presenting cells (aAPC) for propagating
melanoma-specific T cells from both TIL and peripheral blood.
K562 were genetically modified to function as ‘‘generic’’ aAPC
for in vitro propagation of T cells with central/effector memory
phenotypes by enforced expression of the costimulatory molecules
CD86 and 41BB-L in addition to membrane-bound versions of the
cytokines IL7/IL15/IL21. As K562 do not express endogenous
HLA A and B molecules engendering allogeneic responses, they
were genetically modified as ‘‘specialized’’ aAPC using the Sleeping
